Veru Inc. Overview
Pro stress-test →Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for treatment of cardiometabolic and inflammatory diseases, with two lead late-stage small molecule drug candidates: enobosarm and sabizabulin. The company is primarily positioned in the rapidly expanding obesity and weight management market through its lead asset enobosarm.
Strategic Profile
Pro stress-test →Enobosarm is a selective androgen receptor modulator (SARM) being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. The company achieved regulatory clarity from the FDA for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, with Phase 2b PLATEAU study planned to start Q1 2026.
Competitive Landscape
Pro stress-test →Veru focuses on addressing muscle loss in patients undergoing weight loss therapy with GLP-1 drugs, positioning against existing GLP-1 monotherapies. Primary competition comes from large pharma companies (Novo Nordisk, Eli Lilly, Viking Therapeutics) developing obesity treatments, though Veru's muscle-preservation angle offers differentiation in the expanding weight management category.
Industry Context
Veru Inc. operates in Biopharmaceutical - Cardiometabolic & Inflammatory Diseases.
Key facts
Founded: 1971 · Headquarters: Miami, FL · Market cap: ~$300M